NEW YORK – CureDuchenne Ventures has made a $1 million initial investment in Entos Pharmaceuticals, supporting its development of a genetic medicine for Duchenne muscular dystrophy (DMD).

The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.

A £129 million government grant will help the firm establish new R&D centers for advancing new cancer immunotherapies including personalized mRNA vaccines.

The company plans to use the money to continue an ongoing global Phase II trial of the drug in several BRAF-altered tumor types.

NEW YORK – Sarepta Therapeutics on Wednesday said that the UK's Medicines & Healthcare Products Regulatory Agency has lifted the clinical hold on a Phase III study of its Duchenne muscular dystrophy ...

Researchers tested the performance of the whole-genome sequencing-based assay head-to-head against ctDNA and ddPCR assays.

Scientists are seeking new grant opportunities, founding their own for-profit ventures, and exploring other approaches to ...

NEW YORK – The first patient with an advanced, MTAP-deleted solid tumor has received Tango Therapeutics' PRMT5 inhibitor TNG456 in a Phase I/II trial, the company said Wednesday. The Boston-based firm ...

NEW YORK – Fractyl Health has submitted the first module of a clinical trial application with European regulators seeking to begin a first-in-human study of its investigational gene therapy for type 2 ...

NEW YORK – PeproMene Bio will expand the ongoing Phase I PMB-102 study of its BAFF-R-targeted CAR T-cell therapy PMB-CT01 after showing initial efficacy in seven lymphoma patients, the firm said ...